Heron Therapeutics (HRTX) executive compensation, 2026 proxy

Craig Collard, Chief Executive Officer, was paid $3.5M in 2025, up 4% from $3.4M the year before. The CEO-to-median-employee pay ratio was 13:1, on median employee pay of $268,890.

Filed
April 30, 2026
Annual meeting
June 11, 2026
Pay year
2025
Named executives
4
CEO total pay
$3.5M+4% vs prior year
CEO to median employee
13:1median $268,890
CEO pay in equity
65%$2.3M in awards
Prior say-on-pay support
96%of votes cast
CEO Target Bonus
75%Percentage of base salary
Say-on-Pay Support
96%For fiscal 2024 compensation
Median Employee Pay
$268,890Annual total compensation

How Collard was paid

$3.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary20%Stock awards27%Option awards38%Non-equity incentive15%All other compensation0%

Named executive officers

ExecutiveTotal
Craig CollardChief Executive Officer$3,516,291
Ira DuarteEVP, Chief Financial Officer$1,630,678
William ForbesEVP, Chief Development Officer$1,687,765
Mark HensleyEVP, Chief Operating Officer$4,307,500

What changed and why

  • $3.5MCEO Craig Collard received total compensation of $3,516,291 for fiscal 2025 compared to $3,395,492 for fiscal 2024.
  • 96%The 2025 Say-on-Pay proposal received approximately 96% support from stockholders.
  • Mark Hensley joined the company as Chief Operating Officer during fiscal 2025.
  • The ratio of CEO to median employee pay was 13.08 to 1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.